The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,370.00
Bid: 12,370.00
Ask: 12,374.00
Change: 38.00 (0.31%)
Spread: 4.00 (0.032%)
Open: 12,350.00
High: 12,432.00
Low: 12,314.00
Prev. Close: 12,332.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FOREX-Dollar hits two-year lows as traders ignore U.S. stimulus delays

Wed, 30th Dec 2020 08:57

* Dollar falls to lowest since April 2018

* Pound boosted by UK Oxford/AstraZeneca vaccine approval

* Aussie, Kiwi gain versus dollar

* Graphic: World FX rates in 2020 https://tmsnrt.rs/2RBWI5E

LONDON, Dec 30 (Reuters) - The dollar sunk to its lowest in
more than two years in Asian trading on Wednesday and riskier
currencies surged, as investors looked past the latest delay in
U.S. fiscal stimulus and bet that global market risk appetite
would increase in 2021.

U.S. Senate Majority Leader Mitch McConnell on Tuesday
blocked a vote on increasing COVID-19 relief payments to $2,000,
adding another delay to fractious negotiations over fiscal
stimulus.

But market sentiment was upbeat as investors remained
optimistic that a fiscal stimulus deal will be eventually
reached, lessening demand for the safe-haven dollar.

The latest setback "doesn’t really matter too much for
investors as they have been over the moon on the back of news
that there is still plenty of fiscal support for the U.S.
economy," Naeem Aslam, chief market analyst at Avatrade, said in
a note.

Analysts expect the dollar to weaken further in 2021 as U.S.
President-elect Joe Biden is expected to push for even more
measures to support the U.S. economy.

The "risk-on" moves in currency markets peaked in the Asian
session on Wednesday, then eased off as European markets opened.

At 0816 GMT, the dollar was down around 0.1% versus a basket
of currencies, at 89.895, having dropped as low as 89.711
overnight. The euro was up at $1.226.

The Australian dollar - seen as a liquid proxy for global
risk appetite - was up 0.6% on the day at 0.76475 at 0825 GMT
. The New Zealand dollar also hit two-year highs
.

The dollar lost out to the Japanese yen, with dollar-yen
down 0.2% at 103.34 at 0834 GMT.

In Europe, sentiment was buoyed by Britain becoming the
first country in the world to approve the COVID-19 vaccine
developed by AstraZeneca and Oxford University.

The British pound was up against the dollar, at $1.3538, but
little changed against the euro, as traders returning from the
Christmas break digested the Brexit deal struck on Dec. 24.

Although the agreement avoids a chaotic no-deal exit, it
does not cover services, which make up 80% of the British
economy.

Commonwealth Bank of Australia senior currency strategist
Elias Haddad wrote in a note to clients that the fact that the
deal does not provide an equivalence framework for financial
service and growing support for Scottish independence are new
headwinds for the pound.

Euro zone government bond yields edged up by around one
basis point, with Germany's benchmark 10-year yield at -0.56% at
0827 GMT.

Elsewhere, Bitcoin reached a record high of $28,599.99,
taking its yearly gain for the world's most popular
cryptocurrency past 295%.

(Reporting by Elizabeth Howcroft, editing by Larry King)

More News
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.